APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Diagnostics Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Diagnostics Service Market Outlook and Growth Opportunities 2026

Report ID 17408507042 January 2026195 pages

Choose your research edition.

Industry ResearchCancer Diagnostics Service Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Diagnostics Service Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Cancer Diagnostics Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Diagnostics Service Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Diagnostics Service Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Diagnostics Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Diagnostics Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Diagnostics Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Diagnostics Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Diagnostics Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Diagnostics Service market include Illumina, BGI Genomics Co.,Ltd., Agilent Technologies, Macrogen, Pacific Biosciences, Abbott, QIAGEN, Siemens Healthcare GmbH and Thermo Fisher Scientific, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cancer Diagnostics Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Diagnostics Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Diagnostics Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cancer Diagnostics Service market.

Cancer Diagnostics Service Segment by Company

Illumina

BGI Genomics Co.,Ltd.

Agilent Technologies

Macrogen

Pacific Biosciences

Abbott

QIAGEN

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

Applied DNA Sciences

Cancer Diagnostics Service Segment by Type

Breast Cancer

Blood Cancer

Lung Cancer

Colorectal Cancer

Ovarian Cancer

Others

Cancer Diagnostics Service Segment by Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Laboratories

Others

Cancer Diagnostics Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Diagnostics Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cancer Diagnostics Service key companies, revenue, market share, and recent developments.

3. To split the Cancer Diagnostics Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cancer Diagnostics Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Diagnostics Service significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Diagnostics Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Diagnostics Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Diagnostics Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Diagnostics Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Diagnostics Service industry.

Chapter 3: Detailed analysis of Cancer Diagnostics Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cancer Diagnostics Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cancer Diagnostics Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Diagnostics Service Industry Trends Table 2. Cancer Diagnostics Service Industry Drivers Table 3. Cancer Diagnostics Service Industry Opportunities and Challenges Table 4. Cancer Diagnostics Service Industry Restraints Table 5. Global Cancer Diagnostics Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Diagnostics Service Revenue Share by Company (2021-2026) Table 7. Global Cancer Diagnostics Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cancer Diagnostics Service Key Company Manufacturing Base & Headquarters Table 9. Global Cancer Diagnostics Service Company, Product Type & Application Table 10. Global Cancer Diagnostics Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cancer Diagnostics Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Breast Cancer Table 15. Significant Companies of Blood Cancer Table 16. Significant Companies of Lung Cancer Table 17. Significant Companies of Colorectal Cancer Table 18. Significant Companies of Ovarian Cancer Table 19. Significant Companies of Others Table 20. Global Cancer Diagnostics Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Cancer Diagnostics Service Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Cancer Diagnostics Service Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Cancer Diagnostics Service Sales Value Share by Type (2021-2026) Table 24. Global Cancer Diagnostics Service Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospitals Table 26. Significant Companies of Ambulatory Surgical Centers Table 27. Significant Companies of Diagnostic Laboratories Table 28. Significant Companies of Others Table 29. Global Cancer Diagnostics Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cancer Diagnostics Service Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Cancer Diagnostics Service Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Cancer Diagnostics Service Sales Value Share by Application (2021-2026) Table 33. Global Cancer Diagnostics Service Sales Value Share by Application (2027-2032) Table 34. Global Cancer Diagnostics Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Cancer Diagnostics Service Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Cancer Diagnostics Service Sales Value Share by Region (2021-2026) Table 37. Global Cancer Diagnostics Service Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Cancer Diagnostics Service Sales Value Share by Region (2027-2032) Table 39. Global Cancer Diagnostics Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Cancer Diagnostics Service Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Cancer Diagnostics Service Sales Value Market Share by Country (2021-2026) Table 42. Global Cancer Diagnostics Service Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Cancer Diagnostics Service Sales Value Market Share by Country (2027-2032) Table 44. Illumina Company Information Table 45. Illumina Business Overview Table 46. Illumina Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Illumina Cancer Diagnostics Service Product Portfolio Table 48. Illumina Recent Development Table 49. BGI Genomics Co.,Ltd. Company Information Table 50. BGI Genomics Co.,Ltd. Business Overview Table 51. BGI Genomics Co.,Ltd. Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. BGI Genomics Co.,Ltd. Cancer Diagnostics Service Product Portfolio Table 53. BGI Genomics Co.,Ltd. Recent Development Table 54. Agilent Technologies Company Information Table 55. Agilent Technologies Business Overview Table 56. Agilent Technologies Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Agilent Technologies Cancer Diagnostics Service Product Portfolio Table 58. Agilent Technologies Recent Development Table 59. Macrogen Company Information Table 60. Macrogen Business Overview Table 61. Macrogen Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Macrogen Cancer Diagnostics Service Product Portfolio Table 63. Macrogen Recent Development Table 64. Pacific Biosciences Company Information Table 65. Pacific Biosciences Business Overview Table 66. Pacific Biosciences Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pacific Biosciences Cancer Diagnostics Service Product Portfolio Table 68. Pacific Biosciences Recent Development Table 69. Abbott Company Information Table 70. Abbott Business Overview Table 71. Abbott Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Abbott Cancer Diagnostics Service Product Portfolio Table 73. Abbott Recent Development Table 74. QIAGEN Company Information Table 75. QIAGEN Business Overview Table 76. QIAGEN Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. QIAGEN Cancer Diagnostics Service Product Portfolio Table 78. QIAGEN Recent Development Table 79. Siemens Healthcare GmbH Company Information Table 80. Siemens Healthcare GmbH Business Overview Table 81. Siemens Healthcare GmbH Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Siemens Healthcare GmbH Cancer Diagnostics Service Product Portfolio Table 83. Siemens Healthcare GmbH Recent Development Table 84. Thermo Fisher Scientific, Inc. Company Information Table 85. Thermo Fisher Scientific, Inc. Business Overview Table 86. Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Product Portfolio Table 88. Thermo Fisher Scientific, Inc. Recent Development Table 89. Applied DNA Sciences Company Information Table 90. Applied DNA Sciences Business Overview Table 91. Applied DNA Sciences Cancer Diagnostics Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Applied DNA Sciences Cancer Diagnostics Service Product Portfolio Table 93. Applied DNA Sciences Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Cancer Diagnostics Service Product Image Figure 2. Global Cancer Diagnostics Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Diagnostics Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Diagnostics Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Breast Cancer Image Figure 8. Blood Cancer Image Figure 9. Lung Cancer Image Figure 10. Colorectal Cancer Image Figure 11. Ovarian Cancer Image Figure 12. Others Image Figure 13. Global Cancer Diagnostics Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Cancer Diagnostics Service Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Diagnostics Service Sales Value Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Ambulatory Surgical Centers Image Figure 18. Diagnostic Laboratories Image Figure 19. Others Image Figure 20. Global Cancer Diagnostics Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Cancer Diagnostics Service Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Cancer Diagnostics Service Sales Value Share by Application (2021-2032) Figure 23. Global Cancer Diagnostics Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Cancer Diagnostics Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Cancer Diagnostics Service Sales Value (2021-2032) & (US$ Million) Figure 26. North America Cancer Diagnostics Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Cancer Diagnostics Service Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Cancer Diagnostics Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Cancer Diagnostics Service Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Cancer Diagnostics Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Cancer Diagnostics Service Sales Value (2021-2032) & (US$ Million) Figure 32. South America Cancer Diagnostics Service Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Cancer Diagnostics Service Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Cancer Diagnostics Service Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Cancer Diagnostics Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Breast Cancer
  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Others
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others
Companies covered
  • Illumina
  • BGI Genomics Co.,Ltd.
  • Agilent Technologies
  • Macrogen
  • Pacific Biosciences
  • Abbott
  • QIAGEN
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
  • Applied DNA Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Diagnostics Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Diagnostics Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cancer Diagnostics Service Market Dynamics
  1. 2.1 Cancer Diagnostics Service Industry Trends
  2. 2.2 Cancer Diagnostics Service Industry Drivers
  3. 2.3 Cancer Diagnostics Service Industry Opportunities and Challenges
  4. 2.4 Cancer Diagnostics Service Industry Restraints
3 Cancer Diagnostics Service Market by Company
  1. 3.1 Global Cancer Diagnostics Service Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Diagnostics Service Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Diagnostics Service Company Ranking (2024-2026)
  4. 3.4 Global Cancer Diagnostics Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Cancer Diagnostics Service Company Product Type and Application
  6. 3.6 Global Cancer Diagnostics Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cancer Diagnostics Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cancer Diagnostics Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cancer Diagnostics Service Market by Type
  1. 4.1 Cancer Diagnostics Service Type Introduction
  2. 4.1.1 Breast Cancer
  3. 4.1.2 Blood Cancer
  4. 4.1.3 Lung Cancer
  5. 4.1.4 Colorectal Cancer
  6. 4.1.5 Ovarian Cancer
  7. 4.1.6 Others
  8. 4.2 Global Cancer Diagnostics Service Sales Value by Type
  9. 4.2.1 Global Cancer Diagnostics Service Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Cancer Diagnostics Service Sales Value by Type (2021-2032)
  11. 4.2.3 Global Cancer Diagnostics Service Sales Value Share by Type (2021-2032)
5 Cancer Diagnostics Service Market by Application
  1. 5.1 Cancer Diagnostics Service Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.1.3 Diagnostic Laboratories
  5. 5.1.4 Others
  6. 5.2 Global Cancer Diagnostics Service Sales Value by Application
  7. 5.2.1 Global Cancer Diagnostics Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cancer Diagnostics Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Cancer Diagnostics Service Sales Value Share by Application (2021-2032)
6 Cancer Diagnostics Service Regional Value Analysis
  1. 6.1 Global Cancer Diagnostics Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Diagnostics Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cancer Diagnostics Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cancer Diagnostics Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Diagnostics Service Sales Value (2021-2032)
  7. 6.3.2 North America Cancer Diagnostics Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cancer Diagnostics Service Sales Value (2021-2032)
  10. 6.4.2 Europe Cancer Diagnostics Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cancer Diagnostics Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cancer Diagnostics Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cancer Diagnostics Service Sales Value (2021-2032)
  16. 6.6.2 South America Cancer Diagnostics Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cancer Diagnostics Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cancer Diagnostics Service Sales Value Share by Country, 2025 VS 2032
7 Cancer Diagnostics Service Country-level Value Analysis
  1. 7.1 Global Cancer Diagnostics Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Diagnostics Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cancer Diagnostics Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cancer Diagnostics Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cancer Diagnostics Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cancer Diagnostics Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cancer Diagnostics Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Illumina
  2. 8.1.1 Illumina Company Information
  3. 8.1.2 Illumina Business Overview
  4. 8.1.3 Illumina Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Illumina Cancer Diagnostics Service Product Portfolio
  6. 8.1.5 Illumina Recent Developments
  7. 8.2 BGI Genomics Co.,Ltd.
  8. 8.2.1 BGI Genomics Co.,Ltd. Company Information
  9. 8.2.2 BGI Genomics Co.,Ltd. Business Overview
  10. 8.2.3 BGI Genomics Co.,Ltd. Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BGI Genomics Co.,Ltd. Cancer Diagnostics Service Product Portfolio
  12. 8.2.5 BGI Genomics Co.,Ltd. Recent Developments
  13. 8.3 Agilent Technologies
  14. 8.3.1 Agilent Technologies Company Information
  15. 8.3.2 Agilent Technologies Business Overview
  16. 8.3.3 Agilent Technologies Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Agilent Technologies Cancer Diagnostics Service Product Portfolio
  18. 8.3.5 Agilent Technologies Recent Developments
  19. 8.4 Macrogen
  20. 8.4.1 Macrogen Company Information
  21. 8.4.2 Macrogen Business Overview
  22. 8.4.3 Macrogen Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Macrogen Cancer Diagnostics Service Product Portfolio
  24. 8.4.5 Macrogen Recent Developments
  25. 8.5 Pacific Biosciences
  26. 8.5.1 Pacific Biosciences Company Information
  27. 8.5.2 Pacific Biosciences Business Overview
  28. 8.5.3 Pacific Biosciences Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pacific Biosciences Cancer Diagnostics Service Product Portfolio
  30. 8.5.5 Pacific Biosciences Recent Developments
  31. 8.6 Abbott
  32. 8.6.1 Abbott Company Information
  33. 8.6.2 Abbott Business Overview
  34. 8.6.3 Abbott Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Abbott Cancer Diagnostics Service Product Portfolio
  36. 8.6.5 Abbott Recent Developments
  37. 8.7 QIAGEN
  38. 8.7.1 QIAGEN Company Information
  39. 8.7.2 QIAGEN Business Overview
  40. 8.7.3 QIAGEN Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 QIAGEN Cancer Diagnostics Service Product Portfolio
  42. 8.7.5 QIAGEN Recent Developments
  43. 8.8 Siemens Healthcare GmbH
  44. 8.8.1 Siemens Healthcare GmbH Company Information
  45. 8.8.2 Siemens Healthcare GmbH Business Overview
  46. 8.8.3 Siemens Healthcare GmbH Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Siemens Healthcare GmbH Cancer Diagnostics Service Product Portfolio
  48. 8.8.5 Siemens Healthcare GmbH Recent Developments
  49. 8.9 Thermo Fisher Scientific, Inc.
  50. 8.9.1 Thermo Fisher Scientific, Inc. Company Information
  51. 8.9.2 Thermo Fisher Scientific, Inc. Business Overview
  52. 8.9.3 Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Product Portfolio
  54. 8.9.5 Thermo Fisher Scientific, Inc. Recent Developments
  55. 8.10 Applied DNA Sciences
  56. 8.10.1 Applied DNA Sciences Company Information
  57. 8.10.2 Applied DNA Sciences Business Overview
  58. 8.10.3 Applied DNA Sciences Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Applied DNA Sciences Cancer Diagnostics Service Product Portfolio
  60. 8.10.5 Applied DNA Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst